LDR Spine Secures FDA Approval to Conduct the First Clinical Trial for a Second-Generation Cervical Artificial Disc.AUSTIN, Texas -- Mobi-C(R) Cervical Disc Prosthesis prosthesis (prŏs`thĭsĭs): see artificial limb. prosthesis Artificial substitute for a missing part of the body, usually an arm or leg. Approved for One and Two-Level Artificial Cervical Disc Clinical Trial in the U.S.; Patient Recruitment Now Underway LDR See photocell. Spine, a total spine solution company, announced today that it obtained approval for an Investigational Device Exemption An Investigational Device Exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval (PMA) application or a Premarket Notification [510(k)] submission to Food and (IDE) from the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ). This allows the company to conduct a pivotal human clinical trial to investigate the safety and effectiveness of the Mobi-C(R) cervical artificial disc. This is the only active one and two-level clinical trial approved by the FDA for an artificial cervical disc and the first FDA-approved study of a second-generation cervical disc device. The purpose of the investigation is to establish the safety and effectiveness of the Mobi-C cervical disc prosthesis. The Mobi-C has been used outside the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. since November 2004. Clinical results from Europe were included as part of the investigational application for the Mobi-C clinical study in the United States. The product is currently available in 20 countries throughout Europe and Asia. Texas Back Institute, the largest freestanding spine specialty clinic in the United States, will be the lead clinical site in the investigational study. "For over two years we worked closely with a strong group of spine surgeons to develop Mobi-C and it has been well received, resulting in over 300 implantations in patients outside the United States to date," said Christophe Lavigne, Founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of LDR Medical. "We listened to surgeons who wanted a surgical technique similar to implanting a cervical cage, and we believe the Mobi-C honors their input and is unique in the marketplace. The FDA's approval to conduct a one and two-level clinical trial in the United States is an important step towards bringing this exceptional second-generation device to U.S. patients." Mobi-C has the distinction of being the first second-generation artificial cervical disc to begin U.S. IDE trials. It is commonly used to treat degenerative disc disease Degeneration of the intervertebral disc, which is often called "degenerative disc disease" (DDD) of the spine, is a common disorder of the lower spine and for some people can cause low back pain and/or leg pain (sciatica). in the cervical spine cervical spine Clinical anatomy The region of the vertebral column encompassing C1 through C7 . Its purpose is to restore normal biomechanical Biomechanical may refer to:
"Our investment to fund this important study will exceed $15 million over a three to five year period," said Steve Whitlock, President and CEO of LDR Spine. "We realize that having both a one and two level clinical trial adds additional costs, but we believe it provides surgeons with more options for treating their patients and gives LDR Spine a strategic market advantage because 95 percent of cervical fusion procedures involve one or two levels, a 60 percent increase over single level procedures alone." "The physician feedback we have received on Mobi-C indicates that it may be the easiest device to implant of those currently in development," said Robert Faulkner, managing director and senior analyst for medical devices at JMP JMP Jump JMP Java Memory Profiler JMP Joint Manpower Program JMP Joint Management Plan JMP Joint Marketing Program JMP JCL Manipulation Program JMP Joint Mission Planning (US DoD) JMP Joint Military Program Securities. "Ease of use, development of clinical data for multi-level procedures, and the product's self-centering feature appear likely to make Mobi-C a leading entrant in this potential $1 billion market in the U.S." The study will begin in February 2006 and will follow patients for two years. It will include up to 20 medical centers throughout the United States. LDR Spine supplies U.S. surgeons with innovative spinal solutions in partnership with LDR Medical of Troyes, France. LDR Spine works closely with surgeons to develop implantable systems and instrumentation that restore optimum stability and mobility to patients, and make spine surgery more reproducible and easier to perform. More information is located at www.ldrspine.com. |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion